A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays
- 1 January 2013
- journal article
- research article
- Published by Elsevier BV in Human Pathology
- Vol. 44 (1), 29-38
- https://doi.org/10.1016/j.humpath.2012.05.009
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- ERG gene rearrangement status in prostate cancer detected by immunohistochemistryVirchows Archiv, 2011
- Cellular context in epigenetics: Quantitative multicolor imaging and automated per-cell analysis of miRNAs and their putative targetsMethods, 2010
- Detection of TMPRSS2 Gene Deletions and Translocations in Carcinoma, Intraepithelial Neoplasia, and Normal Epithelium of the Prostate by Direct Fluorescence In Situ HybridizationDiagnostic Molecular Pathology, 2010
- Androgen receptor expression is associated with prostate cancer‐specific survival in castrate patients with metastatic diseaseBJU International, 2010
- A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer BiomarkersJournal of Clinical Oncology, 2008
- TMPRSS2-ERG Gene Fusion Causing ERG Overexpression Precedes Chromosome Copy Number Changes in Prostate Carcinomas, Paired HGPIN LesionsNeoplasia, 2006
- Multispectral imaging in biology and medicine: Slices of lifeCytometry Part A, 2006
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- Androgen and Oestrogen Receptor Status in Benign and Neoplastic Prostate DiseaseBritish Journal of Urology, 1989